Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, Nit Picking - We live in different worlds
"A highly detailed person makes sure these things are right the first time."
OK, but I've never been a highly detailed person, and never will be. In my experience the details can be important in a smooth running business, but are nearly irrelevant in a startup. Birthing is inherently a messy affair.
The 2008 financial crisis was not caused by balance sheets with arithmetic errors, late filings or other simple accounting errors. It was caused by gross negligence, and that's what I'm looking to avoid in a start-up business. Errors in DECN's financial statements have been brought up every few months since I first invested in DECN in late 2013. Other than implied causes of impending death spirals and immanent sub-penny share prices, they haven't resulted in ANY impact that I could discern. They may have instilled FUD in potential investors, but that's not one of my objectives.
If the financial statement errors are extremely important to you, that's OK. Like I said, we appear to live in different worlds. But if your trying to assert that I "should" be vitally concerned with arithmetic mistakes, you're dead wrong.
DECN's financial reports - Big Issue?
To me, simple arithmetic errors, or delaying an audited report by a few days are not big things. They are way down on my list of important things to know about DECN. I'm interested in things that indicate business progress (or lack thereof), not accounting details.
I agree that financial reports are very important. But incessantly picking at the details is boring and pedestrian to me.
What say you?
DECN-JNJ Infringement Suits: Turnabout Is Fair Play
Much more to come real soon
DECN-JNJ Infringement Suits: Turnabout Is Fair Play
Much more to come real soon
Diagnosis of JNJ’s DECN Problem: Hubris
FBI starts probing J&J’s medical device linked to uterine cancer
Written by Tanya Campbell on 30 May 2015
FBI starts probing J&J’s medical device linked to uterine cancer
Investigators from the Federal Bureau of Investigation (FBI) have started probing a surgical gynecological tool that has repeatedly been linked to spreading of uterine cancer in women during a procedure. The controversial took belongs to pharmaceutical products maker Johnson & Johnson (J&J).
According to the investigation by FBI, the pharmaceutical company Johnson & Johnson, the largest manufacturer of the power morcellator, was familiar about the risk of the device and didn't warn customers and physicians. As per the reports, the device was pulled off in 2014, but some other morcellator manufacturers continued selling the device.
A spokeswoman from the FBI, New Jersey office, did not disclose anything about the investigation. On the other side, a spokesperson for Johnson & Johnson's Ethicon division said that the company has not been contacted by FBI regarding the device.
The Wall Street Journal contacted the three individuals who were questioned by the FBI office in Newark about the morcellator device. An anesthesiologist, Dr. Amy Reed, has been among the people contacted by the FBI. Reed underwent a hysterectomy for fibroid removal about two years ago just to find out that the morcellator had made her cancer worse. Currently, Reed and her husband have been protesting to ban the device to save women's lives.
Sarah Robinson, a physician assistant in Los Altos, was also contacted by the FBI about two months ago. While talking to the Wall Street Journal, Robinson said she was testified at a Food and Drug Administration hearing on the device. According to Robinson, she also created a list of ladies families who were supporting the ban of morcellator device. She sent a list of about 386 people to FBI.
The investigation by FBI followed a warning that was issued by FDA in November 2014. The warning said, "The device shouldn't be used on the vast majority of women. One in 350 who underwent the procedure had an unsuspected cancer sarcoma." The agency also called for a 'black-box' warning on the tool.
OK, I get you're postulating
But if it's not pricing based solely on JNJ, I still don't know what your point is.
DECN Test Strip Prices Are Preliminary
No one, including DECN knows what the price of the Test Strips will be 3 months after full launch.
Discussion about DECN pricing strategy may be fun, but it's like who is going to win the next professional ball game.
DECN's Pricing Strategy
"Unless again,as I've theorized before,maybe this is only mean't to be a litigation play...and as some have said is "posturing"..."strong arming" J&J into a position of settlement through an effort to "wreck" J&J's Onetouch profit profile."
I disagree.
Occam's razor (i.e. the simplist explanation is usually the right one) seems applicable here. Perhaps it's just a low promotional price. This seems a lot more plausable than imagining a businees strategy solely focused on the JNJ settlement. It could also it be a signal to others to stay away? It's easy to imagine a dozen other reasons why this was the price chosen.
YouTube Commercial
Scoop, I agree with you opinion on this. I don't think the Commercial on YouTube is ready for mass advertising on any media. But I trust that DECN knows this and will fix it, potentially with the help of Retail Monster.
I don't care about addition errors in the financial reports.
I'm hearing the DECN Settlement Is YUGE!
Just a rumor, but if true, could turn into real financial results that ALL of us care about.
"I seem to be the only one astonished"
I'm not - really - I'm not even surprised.
I agree that most of the items you listed are important, but I think they are just low-level indications of execution. To me, the most important metrics are about revenue and profit. It will be awhile before we see meaningful financial results.
I have no interest in speculating about ramp-up details. I'm a big picture kind of guy, and have never sweated the details unless they were critical to me and I could do something about them. The points you raise are not critical to me NOW, and there is nothing I can do about them, other than sell my shares (which I'm not going to do).
And I suspect - more to come when the word spreads.
"This stinky pinky is horrible ain't it?"
Yeah, right
It seems some have trouble distinguishing the difference between a cesspool and a champagne bath.
Scott,
I really don't know, and I don't think anyone else does either. DECN is effectively a tiny startup addressing a huge market with a potentially disruptive product and patents. If marketing and distribution actually turns out to be strong for the US, and is matched by product quality and manufacturing volume, the potential is great.
But I think you were asking for an actual number for the price per share. Others are probably better qualified to provide that than I am.
So enough of my disclaimers. If things go very well (not perfect, but not bush-league execution), my best guess about the upside is $5 in 12 months and $20 in 24 months. My expected price per share in 12 months is about $2 and I don't have one about 24 months out.
But if things go really well or really poorly, my guesses will probably be flawed and worthless.
Good luck!
I've Acquired A Taste For This Stinky Pink
A supposed death spiral driven by hedge fund selling and serious dilution of E shares is starting to be overwhelmed by investor interest.
Is it a blip? Highly unlikely. It's more like the start of something really big, and very good (for longs).
Let's check back and see in July.
Bad Boy, Bad - Why didn't you sell?
Because we knew better. LOL!
JNJ Appeal To Delay DECN Settlement Denied
stckdytrdr Tuesday, 05/10/16 12:59:01 PM
Game over. We win.
LIFESCAN SCOTLAND, LTD. v. PHARMATECH SOLUTIONS, INC. 2
and thereafter the petition for rehearing en banc was referred to the circuit judges who are in regular active service. Upon consideration thereof, IT IS ORDERED THAT: The petition for panel rehearing is denied. The petition for rehearing en banc is denied. The mandate of the court will issue May 17, 2016.
FOR THE COURT May 10, 2016 /s/ Peter R. Marksteiner Date Peter R. Marksteiner Clerk of Court
No one here, knows JNJ's defeat terms
Hypothetical speculation can be titillating, but it's a lousy basis for investment decisions.
Hedge funds claiming DECN dog food! LOL
Ridiculous? Of course. Typical FUD trying to intimidate small OTC investors.
Anyone wonder why this is done?
The game has just begun!
We've been hearing about "sell now before it's too late" and impending "death spirals" for years. I think they have all been FUD posts.
I think it would be foolish to sell before we have any information on the Settlement. Upside is much greater than downside.
Let's revisit selling at $0.40 in July
I'm a small DECN shareholder and I am paying attention. My cost basis is below $0.35. I'm not going to sell early because of some pink sheet forum FUD. I think the upside potential grossly out-weighs the downside potential here at $0.40. We're still waiting for the news about the Settlement and market expansion. When it comes, I expect a big spike up.
It's not personal, it's just business. I believe this guidance is bad advice.
"Hopefully the small DECN shareholder is paying attention.
For anyone with a cost basis below .35/share, you've had a wonderful opportunity to cash out.
Nothing lasts forever, hedge funds are heavily in play again, and it appears that DECN is unloading common stock at a ridiculous rate right now."
Maybe this is yet another death spiral forecast that turns out to be false, or maybe not. We'll see. But I think it is foolish to sell at $0.40
"we can anticipate a continued decline"
I agree with the premise of your post. That is, the share price drifting lower until we get some hard news that is very positive.
I suspect I'm like many others. I don't plan to sell any shares, nor to I plan to buy any until we do see some real news. The de facto float is very low, so volume will continue to drift lower. But, I don't think we're going to see the 20s, barring some major bad news.
There is also a flip side. Any very positive news, will likely make it impossible for anyone buy shares below $1. To me, the odds of missing a jump is the greater risk. So I'm sitting pat.
Driving DECN out of business seems increasingly unlikely
I've heard that JNJ is testing an innovative new offering of 20lbs of North Korean dog food as part of their OneTouch "Bright New Day" marketing program for North Korea. All new customers, will be elligible for this tasty treat with proof of purchase of at least 100 genuine OneTouch test strips. This is an exciting exclusively for new North Korean customers.
My understanding is that JNJ is searching for new markets, since their existing test strip market is expected to rapidly shrink.
I understand JNJ is testing an innovative new offering of 20lbs of North Korean dog food as part of their "Bright New Day" marketing program for North Korea.
My understanding is they are searching for new markets since their existig test strip market looks like it's going to be overrun by GenUltimate!
Sorry - Amazon search on genultimate confirms that your facts are correct as does your provided link at:
http://www.fullcirclediabetes.com/
Your Genultimate! "facts" seem different
Why do they differ from the "facts" in some earlier posts today?
Thanks
I was lucky enough to buy some shares at $0.08. But there were less than $10K bought at $0.07.
Duh - I feel a little dumb
It's not like I don't use Google very often. Apparently, I've been mentally filtering out those tabs on the search results for many years. And I fancy myself as a deep techy.
Oh well - Thanks!
OK - thanks.
FYI, I have no idea what a Google shopping tab is. Perhaps we have our systems configured differently, or Google's interfaces differ by country. I happen to be in the US.
I'm not sure if we are seeing the same thing.
The first line I see is did you mean "Penultimate"?
If that is what you are referring to, it's not unusual. Search engines have progressed far beyond literal searches. They actually parse phrases and guess at the best match for your query. Since GenUltimate probably hasn't been searched that often. Google is guessing that you made some type of mistake. Its checks are not just about spelling, they also include meaning. So the best semantic search result, according to Google's search algorithm and search history was Penultimate.
If I misunderstood your question, and went off the deep-end over explaining - sorry.
That's a reasonable question
But I don't know the answer and I don't recall any one, on either board, doing anything more than speculating about it. It's unclear how to value the potential, given that there haven't been any claims filed. To me, the odds are so low that the expected value is down in the noise level, compared with other potential impending DECN events.
It would be great to find out that DECN's new patents have a broad value, beyond a negotiating card with JNJ. But it doesn't appear to me that they currently do.
I'd love to find out I'm mistaken - aka wrong
"I say KB maybe carves out the Bio-sensor/Test strip business part of his opportunities and pursue maybe the Pet food Industry avenue."
OK, thanks for your opinion.
Potential scenarios which only include negative possibilities are not credible to me
The updated question to the hypothetical scenario about a DECN by JNJ is once again all negative for DECN investors.
Would the scenario become more credible by adding a few potential positive points to the unlikely possibility of a buy-out? Nope. Because I'm confident that a buy-out isn't going to happen. So adding more information to the posted scenario would just be more noise.
No, the theory doesn't sound about right
1. I don't think a buy-out of DECN by JNJ is plausible. The polarization between the warring camps, after 5 years of legal suppression by JNJ, makes a buy-out improbable. And the potential business growth for DECN is looking better every month. I don't think KB is going to abandon this ship while the voyage is looking Much more likely to be successful. As you may know, some folks have posted that DECN probably accepted a smaller settlement payment from JNJ, in return for the freedom to pursue their market without JNJ's legal shackles. Hooyah!
2. Almost all of the points in the posted JNJ buy-out scenario are pointing out hypothetical uncertainties. And almost every one of them, if they turned out to be true, would be a negative for current individual DECN stock holders.
3. Why don't I add some potential positives for a buy-out to add to the posted scenario? Because it's a hypothetical fantasy that I firmly believe will never be played out. So what would be the point? Why should I contribute to a scenario that could cause existing individual investors to Fear DECN's future, or become more Uncertain about it, or Doubt the wisdom of their existing investment?
I am a long-term individual investor in DECN. I have no interest in contributing to hypothetical information about DECN that is likely to be interpreted as FUD by many.
You too Scoop
How about we both back off a little bit do a better job of communicating?
Ok...now I'm too focused.
Only because of "your not focusing".
The formal judgement and reporting of cases is a rigid process and rightly so. Negotiations are much more flexible and can transcend case boundaries because they are all about coming to an agreement without needing a court judgement. There are no reporting rules for a negotiation outside the court system, that happens to be mediated by a Federal Judge. (OK, I fudged a little, but not much).
So yes, the Settlement terms have not been disclosed.